Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

| About GlobalData

1 Age-Related Macular Degeneration: Executive Summary

1.1 AMD market will grow significantly during the forecast period, reaching sales of $22.8 billion in 2031

1.2 Development of cell-based and gene therapies represent a new paradigm for AMD

1.3 Reducing treatment burden is an important unmet need for wet AMD

1.4 Treatment for geographic atrophy and dry AMD represent an important unmet need for AMD

1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Overview

3.1.2 Etiology

3.1.3 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD

4.4.4 Forecast assumptions and methods: total prevalent cases of GA

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, late wet AMD, and GA

4.5 Epidemiological forecast for AMD (2021–31)

4.5.1 Total prevalent cases of AMD

4.5.2 Age-specific total prevalent cases of AMD

4.5.3 Sex-specific total prevalent cases of AMD

4.5.4 Total prevalent cases of early AMD

4.5.5 Total prevalent cases of late AMD

4.5.6 Total prevalent cases of late dry AMD

4.5.7 Total prevalent cases of late wet AMD

4.5.8 Total prevalent cases of GA

4.5.9 Diagnosed prevalent cases of AMD

4.5.10 Age-specific diagnosed prevalent cases of AMD

4.5.11 Sex-specific diagnosed prevalent cases of AMD

4.5.12 Diagnosed prevalent cases of early AMD

4.5.13 Diagnosed prevalent cases of late AMD

4.5.14 Diagnosed prevalent cases of late dry AMD

4.5.15 Diagnosed prevalent cases of late wet AMD

4.5.16 Diagnosed prevalent cases of GA

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Longer-acting anti-VEGF therapies

7.3 Treatment for GA

7.4 Availability or accessibility of specialists and patient wait times

7.5 Less invasive drug formulations

7.6 Early diagnosis of patients and increasing awareness of AMD

8 R&D Strategies

8.1 Overview

8.1.1 Focus on the development of longer-acting therapies

8.1.2 Diversifying into gene therapies for AMD

8.1.3 Development of cell therapies for AMD

8.2 Clinical trials design

8.2.1 Consideration of endpoints for the whole spectrum of AMD

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist/Reviewers

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table 1: AMD: key metrics in the 7MM

Table 2: Biological pathways associated with AMD risk genes

Table 3: The four-stage AREDS classification of AMD

Table 4: Symptoms of AMD

Table 5: Risk factors and comorbid conditions associated with AMD

Table 6: Treatment guidelines for AMD

Table 7: Top 10 deals by value, 2016–21

Table 8: AMD market – global drivers and barriers, 2021–2031

Table 9: Key events impacting sales for AMD in the US, 2021–2031

Table 10: AMD market – drivers and barriers in the US, 2021–2031

Table 11: Key events impacting sales for AMD in the 5EU, 2021–2031

Table 12: AMD market – drivers and barriers in the 5EU, 2021–2031

Table 13: Key events impacting sales for AMD in Japan, 2021–2031

Table 14: AMD market – drivers and barriers in Japan, 2021–2031

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for AMD in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in AMD during the forecast period

Figure 3: Competitive assessment of recently approved and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD

Figure 5: 7MM, total prevalence of AMD, men and women, ages ≥50 years, %, 2021

Figure 6: 7MM, diagnosed prevalence of AMD, men and women, ages ≥50 years, 2021

Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD

Figure 8: 7MM, sources used to forecast the total prevalent cases of GA and diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD

Figure 9: 7MM, total prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021

Figure 10: 7MM, total prevalent cases of AMD by age, both sexes, N, 2021

Figure 11: 7MM, total prevalent cases of AMD, by sex, ages ≥50 years, N, 2021

Figure 12: 7MM, total prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021

Figure 13: 7MM, total prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021

Figure 14: 7MM, total prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021

Figure 15: 7MM, total prevalent cases of late wet AMD, both sexes, ages ≥50 years, N, 2021

Figure 16: 7MM, total prevalent cases of GA, both sexes, ages ≥50 years, N, 2021

Figure 17: 7MM, diagnosed prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021

Figure 18: 7MM, diagnosed prevalent cases of AMD by age, both sexes, N, 2021

Figure 19: 7MM, diagnosed prevalent cases of AMD, by sex, ages ≥50 years, N, 2021

Figure 20: 7MM, Diagnosed prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021

Figure 21: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021

Figure 22: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021

Figure 23: 7MM, diagnosed prevalent cases of late wet AMD, both sexes, ages ≥50 years, N, 2021

Figure 24: 7MM, diagnosed prevalent cases of GA, both sexes, ages ≥50 years, N, 2021

Figure 25: Amsler grid, as viewed by patients with normal vision and with wAMD

Figure 26: Unmet needs and opportunities in AMD

Figure 27: Overview of the development pipeline in AMD

Figure 28: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AMD in the 7MM during the forecast period

Figure 29: Competitive assessment of recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 30: Competitive assessment of the pipeline drugs benchmarked against the standard of care, Eylea

Figure 31: Analysis of the company portfolio gap in AMD during the forecast period

Figure 32: Global (7MM) sales forecast by country for AMD in 2021 and 2031

Figure 33: Sales forecast by disease subtype for AMD in the US in 2031

Figure 34: Sales forecast for GA in the US in 2031

Figure 35: Sales forecast by class for wAMD in the US in 2021 and 2031

Figure 36: Sales forecast by disease subtype in the 5EU in 2031

Figure 37: Sales forecast by class for wAMD in the 5EU in 2021 and 2031

Figure 38: Sales forecast by class for wAMD in Japan in 2021 and 2031